Annual report pursuant to Section 13 and 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)

v3.23.2
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 0.32 $ 0.32 $ 0.32
Stock Repurchased During Period, Shares (in shares) 222,000 1,576,952 480,000
Average price per share of shares repurchased $ 88.12 $ 102.06 $ 89.95
Net settlement stock options exercised $ 28,893 $ 23,461 $ 19,343
Interest expense 11,215 11,309 13,952
Total other income (expense), net 39,715 4,796 (89,121)
Income Tax Expense (Benefit), Total 53,217 38,287 8,590
Net Deferred Tax Liability 184,005 175,217  
Deferred Income Tax Expense (Benefit), Total (29,799) 7,063 (28,013)
Eminence Biotechnology      
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest 33 70  
Accumulated Other Comprehensive Income      
Net Deferred Tax Liability 3,995 2,480  
Deferred Income Tax Expense (Benefit), Total     1,908
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Other Comprehensive Income      
Interest expense   6,352 8,598
Interest income 4,526    
Total other income (expense), net     512
Reclassification from AOCI, Current Period, Tax, Total $ 1,073 $ 1,493 $ 2,150